Known data from a pilot study that tested an early version the Brain+ Computerized Cognitive Training technology in Parkinson’s Disease has been published

BRAIN+ A/S
Investor update

• Feasibility of use by Parkinson’s patients was shown
• Valuable information gained about patient compliance that is relevant for the products Brain+ is developing for Alzheimer’s and dementia
• Insights from the study have been built into the Computerized Cognitive Training technology, which is currently being tested in people at risk of dementia, and from which results are expected later this year

On January 5th 2022, a study from 2017, testing the feasibility and effect of two different cognitive training programs, was published in the Journal of Dementia and Geriatric Cognitive Disorders. In the study, eight patients with Parkinson’s Disease trained for 8 weeks using the Brain+ Evolution program, an early 2016 version of the Brain+ Computerized Cognitive Training technology.

The study findings provided valuable insights on feasibility and effect of the technology on cognitive dysfunctions. These insights have since been incorporated into the development of next versions of the technology, including a product version called, Brain+ Recover, which subsequently showed that cognitive improvements could be achieved in people with brain injury, and a more recent version currently being evaluated in clinical trials for its effect on cognition in people at risk of dementia.

Parkinson’s Disease is relevant to Brain+’ dementia focus. Parkinson’s disease is a condition with high risk of conversion to dementia, and an estimated 50 to 80 percent of people with Parkinson’s eventually experience dementia as their disease progresses.

The purpose of the pilot study was to test the feasibility and effect on cognitive dysfunctions using two different cognitive training programs against a control group in Parkinson’s Disease. The study was carried out at Bispebjerg Hospital, Department of Neurology and led by Katrine Svaerke and Jesper Mogensen.

The results showed that Brain+ Evolution is feasible to use in patients with Parkinson’s Disease, who were able to complete the program on their own with remote support from the therapist. There was no effect of Brain+ Evolution on the cognitive dysfunctions of Parkinson Disease, but valuable insights were retrieved. These insights have since been incorporated in later versions of the technology that are being tested in clinical studies with results following this year, and in the coming years.

Kim Baden-Kristensen, Co-founder and CEO, Brain+. "We value the close and mutual beneficial collaboration with the academic and medical community. Opportunities, such as this pilot study in Parkinson’s, provide critical input to our product development, while helping to move the therapeutic area forward together with clinicians. We are happy to have contributed to growing the knowledge on cognitive training in Parkinson’s Disease, while gaining key insights to develop our own technologies further. Brain+ will continue to focus on dementia to help people maintain independence and a high quality of life."

Contact Information

CEO, Kim Baden-Kristensen + 45 31393319, E-mail: kim@brain-plus.com, Brain+ A/S, Købmagergade 53, 3.
Certified Advisor: Keswick Global AG, + 43 1 740 408045 , E-mail: info@keswickglobal.com

Published research article

Effects of Computer-Based Cognitive Rehabilitation on Attention, Executive Functions, and Quality of Life in Patients with Parkinson’s Disease: A Randomized, Controlled, Single-Blinded Pilot Study

Svaerke K., Faerk A.K., Riis A., Stiegnitz von Ehrenfels S.E.M., Mogensen J.,  Lokkegaard A

https://www.karger.com/Article/Abstract/520591

About Computerized Cognitive Training

This method engages a user in cognitive exercises, which can be designed as engaging and fun computer-games. The exercises challenge the brain’s functions to the limit of the user’s abilities thus aiming to strengthen the neural networks of the brain related to a particular function, which is being trained. When Computerized Cognitive Training ‘technology’ is being referenced, it refers to the mechanisms of action, exercise designs, program designs and knowhow, and not to a specific product. A product in this context uses one or several of the Brain+ technologies to address a specific unmet need in a specific user segment.

About BRAIN+ [BRAINP]

PROBLEM: Dementia is a terrible condition, crippling a person’s independence and putting a heavy burden also on the family. With an aging population, dementia is threatening to overwhelm the health care systems of the world. New treatments and therapies are greatly needed.

VISION: Making effective dementia treatments available to everyone, digitally.

MISSION: To restore patients’ independence and quality of life by treating and detecting cognitive decline in Alzheimer’s disease and dementia.

SOLUTION: Digitizing best-in-class non-drug dementia therapies and enhancing them with cutting edge digital technologies, together with the world’s leading experts, making them available on computers and smart phones in people’s homes or at the clinic. A therapy here, simply means a person having to actively do something, interacting with a software program or another person, which is stimulating to the brain, or which results in changes in behavior that brings measurable health benefits. Such therapies can be used on their own or be combined with traditional drug treatments.

OUR DNA: We operate like a digital biotech company; our technologies and products are being rigorously tested, scientifically and clinically validated, regulated as medical products, and reimbursed and paid for by the state or health insurances.

POTENTIAL: The global costs of dementia will be $2 trillion in 2030 (or equal to 2/3rds of the entire health care spend of the USA), the estimated market potential which our digital products could address will be $24 billion and growing rapidly, and our target in 2030 is revenue in the hundreds of millions $ based on licensing deals with strategic commercial partners, and we aim to close a first large multi-million $-deal in 2025.

TEAM & TECH: We have built our knowledge base, know-how and network of global expert collaborators, over 10 years, and our technology portfolio is the results of R&D investments of over €10 million, which puts us in a unique position to become a global market leader in digital therapeutic solutions for dementia and Alzheimer’s. We have a team with the deep and necessary expertise to succeed, including our Director of Science & Innovation from Coloplast, our CTO from Lundbeck, our Chief Commercial from Novartis, and our CFO from GN Hearing.